These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28688743)

  • 1. [Detection of RAS genes mutation using the Cobas
    Albertini AF; Raoux D; Neumann F; Rossat S; Tabet F; Pedeutour F; Duranton-Tanneur V; Kubiniek V; Vire O; Weinbreck N
    Bull Cancer; 2017; 104(7-8):662-674. PubMed ID: 28688743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.
    Normanno N; Pinto C; Castiglione F; Fenizia F; Barberis M; Marchetti A; Fontanini G; De Rosa G; Taddei GL
    J Transl Med; 2015 Sep; 13():287. PubMed ID: 26335936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment].
    Bibeau F; Louvet C; Afchain P; Mitry E; Artru P; André T
    Bull Cancer; 2012; 99(7-8):743-51. PubMed ID: 22735045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: a total of 5550 exons sequenced by 15 molecular French laboratories (evaluation of the EGFR mutation status for the administration of EGFR-TKIs in non-small cell lung carcinoma [ERMETIC] project--part 1).
    Beau-Faller M; Degeorges A; Rolland E; Mounawar M; Antoine M; Poulot V; Mauguen A; Barbu V; Coulet F; Prétet JL; Bièche I; Blons H; Boyer JC; Buisine MP; de Fraipont F; Lizard S; Olschwang S; Saulnier P; Prunier-Mirebeau D; Richard N; Danel C; Brambilla E; Chouaid C; Zalcman G; Hainaut P; Michiels S; Cadranel J
    J Thorac Oncol; 2011 Jun; 6(6):1006-15. PubMed ID: 21532509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis.
    Dijkstra JR; Opdam FJ; Boonyaratanakornkit J; Schönbrunner ER; Shahbazian M; Edsjö A; Hoefler G; Jung A; Kotsinas A; Gorgoulis VG; López-Ríos F; de Stricker K; Rouleau E; Biesmans B; van Krieken JH
    J Mol Diagn; 2012; 14(3):187-91. PubMed ID: 22414609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres.
    Boleij A; Tack V; Taylor A; Kafatos G; Jenkins-Anderson S; Tembuyser L; Dequeker E; van Krieken JH
    BMC Cancer; 2016 Oct; 16(1):825. PubMed ID: 27784278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view].
    Blons H; Laurent-Puig P
    Bull Cancer; 2009 Dec; 96 Suppl():S47-56. PubMed ID: 20034870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Method validation according to ISO 15189 and SH GTA 04: application for the detection of KRAS mutations using PCR TaqMan assay].
    Harlé A; Dubois C; Rouyer M; Merlin JL
    Ann Biol Clin (Paris); 2013; 71(5):603-7. PubMed ID: 24113449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The accreditation of a surgical pathology and somatic genetic laboratory (LPCE, CHU of Nice) according to the ISO 15189 norm: Sharing of experience].
    Washetine K; Long E; Hofman V; Lassalle S; Ilie M; Lespinet V; Bonnetaud C; Bordone O; Gavric-Tanga V; Selva E; Reverso-Meinietti J; Sadoulet D; Lacour L; Bille Y; Lavagna R; Grier P; Zahaf K; Mari M; Hofman P
    Ann Pathol; 2013 Dec; 33(6):386-97. PubMed ID: 24331720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
    Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
    Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
    László L
    Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy.
    Thunnissen E; Bovée JV; Bruinsma H; van den Brule AJ; Dinjens W; Heideman DA; Meulemans E; Nederlof P; van Noesel C; Prinsen CF; Scheidel K; van de Ven PM; de Weger R; Schuuring E; Ligtenberg M
    J Clin Pathol; 2011 Oct; 64(10):884-92. PubMed ID: 21947301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma.
    Ishige T; Itoga S; Sato K; Kitamura K; Nishimura M; Sawai S; Matsushita K; Suzuki K; Ota S; Miyauchi H; Matsubara H; Nakatani Y; Nomura F
    Clin Biochem; 2014 Dec; 47(18):340-3. PubMed ID: 25262986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples.
    Cortes U; Guilloteau K; Rouvreau M; Archaimbault C; Villalva C; Karayan-Tapon L
    Exp Mol Pathol; 2015 Oct; 99(2):207-11. PubMed ID: 26163758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.
    Boleij A; Tops BB; Rombout PD; Dequeker EM; Ligtenberg MJ; van Krieken JH;
    Oncotarget; 2015 Jun; 6(17):15681-9. PubMed ID: 25944693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation.
    Richman SD; Fairley J; Butler R; Deans ZC
    J Clin Pathol; 2017 Jan; 70(1):58-62. PubMed ID: 27681846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
    Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
    N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS mutation testing in colorectal cancer.
    Plesec TP; Hunt JL
    Adv Anat Pathol; 2009 Jul; 16(4):196-203. PubMed ID: 19546608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher quality of molecular testing, an unfulfilled priority: Results from external quality assessment for KRAS mutation testing in colorectal cancer.
    Tembuyser L; Ligtenberg MJ; Normanno N; Delen S; van Krieken JH; Dequeker EM
    J Mol Diagn; 2014 May; 16(3):371-7. PubMed ID: 24631467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.